Daniel Thomas O 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
Daniel Thomas O
Director
Transactions
- Conversion
Series B Preferred Stock
2018-06-25−30,028→ 0 total→ Common Stock (11,620 underlying) - Conversion
Common Stock
2018-06-25+24,527→ 101,926 total - Conversion
Series A Preferred Stock
2018-06-25−33,350→ 0 total→ Common Stock (12,907 underlying)
Footnotes (1)
- [F1]The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.